HK1065478A1 - Treatment for attention-deficit hyperactivity disorder - Google Patents

Treatment for attention-deficit hyperactivity disorder

Info

Publication number
HK1065478A1
HK1065478A1 HK04108300.4A HK04108300A HK1065478A1 HK 1065478 A1 HK1065478 A1 HK 1065478A1 HK 04108300 A HK04108300 A HK 04108300A HK 1065478 A1 HK1065478 A1 HK 1065478A1
Authority
HK
Hong Kong
Prior art keywords
hyperactivity disorder
attention
treatment
deficit hyperactivity
hyperactivity
Prior art date
Application number
HK04108300.4A
Other languages
English (en)
Inventor
Daniela Brunner
Daniel W Goodman
Original Assignee
Psychogenics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Psychogenics Inc filed Critical Psychogenics Inc
Publication of HK1065478A1 publication Critical patent/HK1065478A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK04108300.4A 2001-07-20 2004-10-21 Treatment for attention-deficit hyperactivity disorder HK1065478A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30682501P 2001-07-20 2001-07-20
US38293102P 2002-05-23 2002-05-23
PCT/US2002/023081 WO2003007956A1 (fr) 2001-07-20 2002-07-19 Traitement des troubles de deficit de l'attention/hyperactivite

Publications (1)

Publication Number Publication Date
HK1065478A1 true HK1065478A1 (en) 2005-02-25

Family

ID=26975388

Family Applications (1)

Application Number Title Priority Date Filing Date
HK04108300.4A HK1065478A1 (en) 2001-07-20 2004-10-21 Treatment for attention-deficit hyperactivity disorder

Country Status (11)

Country Link
US (5) US7504395B2 (fr)
EP (2) EP1408976B3 (fr)
JP (1) JP5080716B2 (fr)
AT (1) ATE424825T1 (fr)
AU (2) AU2002322539B2 (fr)
CA (1) CA2453837C (fr)
DE (1) DE60231507D1 (fr)
DK (1) DK1408976T5 (fr)
ES (1) ES2323451T7 (fr)
HK (1) HK1065478A1 (fr)
WO (1) WO2003007956A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7048906B2 (en) * 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
ES2323451T7 (es) * 2001-07-20 2011-08-01 Psychogenics Inc. Tratamiento para el trastorno de hiperactividad con deficit de atencion.
US8134029B2 (en) 2002-09-16 2012-03-13 Sunovion Pharmaceuticals Inc. Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine
US8751031B2 (en) * 2004-02-06 2014-06-10 Zircore, Llc System and method for mass custom manufacturing of dental crowns and crown components
MX2008000250A (es) 2005-07-06 2008-03-19 Sepracor Inc Combinaciones de eszopiclona y trans-4-(3,4-diclorofenil)-1,2,3,4- tetrahidro-n-metil-1-naftalenamina o trans 4-(3,4-diclorofenil)-1, 2,3,4-tetrahidro-1-naftalenamina y metodos de tratamiento de menopausia y trastornos del estado de animo, ansiedad y
US9066903B2 (en) 2006-02-28 2015-06-30 The United States Of America As Represented By The Department Of Veterans Affairs Pharmacological treatment of Parkinson's disease
CN103054868B (zh) * 2008-05-30 2016-08-31 赛科基因股份有限公司 用于神经和精神障碍的治疗
CA2759180A1 (fr) * 2009-05-13 2010-11-18 Sunovion Pharmaceuticals Inc. Compositions comprenant de la transnorsertraline et des agonistes/antagonistes du recepteur 1a de la serotonine et leurs applications
MX2011013775A (es) * 2009-06-25 2012-04-20 Alcobra Ltd Un metodo para el tratamiento, alivio de sitomas de, mitigacion, mejoramieto y prevencion de una enfermedad, desorden o condicion cognoscitiva.
WO2011000562A1 (fr) 2009-06-30 2011-01-06 Merz Pharma Gmbh & Co. Kgaa Eltoprazine pour le traitement de certains troubles du mouvement
WO2011000564A1 (fr) 2009-06-30 2011-01-06 Merz Pharma Gmbh & Co. Kgaa Eltoprazine pour le traitement de la pharmacodépendance
US20120190690A1 (en) 2009-06-30 2012-07-26 Merz Pharma Gmbh & Co. Kgaa Eltoprazine for the treatment of weight disorders
US20120136005A1 (en) 2009-06-30 2012-05-31 Merz Pharma Gmbh & Co. Kgaa Eltoprazine for the treatment of anxiety
US8894415B2 (en) * 2009-09-29 2014-11-25 Advanced Training System Llc System, method and apparatus for driver training
WO2014180556A1 (fr) * 2013-05-06 2014-11-13 Merz Pharma Gmbh & Co. Kgaa Arylpipérazines
JP7406285B1 (ja) 2023-03-09 2023-12-27 国立大学法人島根大学 ビリルビン誘発性神経機能障害、黄疸を伴う精神疾患、又はビリルビンｕｄｐ－グルクロン酸転移酵素遺伝子変異に起因する精神疾患を治療、予防又は管理するための医薬組成物

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4039653A (en) * 1974-01-23 1977-08-02 Defoney, Brenman, Mayes & Baron Long-acting articles for oral delivery and process
CH653021A5 (fr) 1981-04-24 1985-12-13 Delalande Sa Derives piperidino, piperazino et homopiperazino, n-substitues par un groupe heterocyclique aromatique, leur procede de preparation et composition therapeutique les contenant.
FR2524312B1 (fr) * 1982-04-01 1985-10-04 Tech Cuir Centre Nouvelles formes de micro-encapsulation de substances medicamenteuses par des couches homogenes de collagene natif
AU577802B2 (en) 1983-10-17 1988-10-06 Duphar International Research B.V. Blood-pressure lowering piperazine derivatives
EP0190472B1 (fr) 1984-12-21 1989-07-12 Duphar International Research B.V Médicaments à activité antipsychotique
ATE81975T1 (de) 1984-12-21 1992-11-15 Duphar Int Res Arzneimittel mit psychotroper wirkung.
GB8521494D0 (en) * 1985-08-29 1985-10-02 Zyma Sa Controlled release tablet
US4797286A (en) * 1985-11-12 1989-01-10 Eli Lilly And Company Orally administerable sustained release pharmaceutical formulations
CA1279645C (fr) 1986-02-27 1991-01-29 Ineke Van Wijngaarden N-piperidinylmethyl-et n-piperazinylmethylazoles a substituant aryle, a proprietes antispychotiques
GB8613689D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
MX173362B (es) 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
DK172628B1 (da) 1987-09-11 1999-08-02 Duphar Int Res Anvendelse af piperazinderivater til fremstilling af lægemidler til behandling af syndromer, der involverer frygt eller fry
US4831031A (en) 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
DK611489A (da) 1988-12-08 1990-06-09 Duphar Int Res Anxiolytisk aktive piperazinderivater og farmaceutiske praeparater med indhold af saadanne forbindelser
GB8830312D0 (en) 1988-12-28 1989-02-22 Lundbeck & Co As H Heterocyclic compounds
SE8904361D0 (sv) 1989-12-22 1989-12-22 Astra Ab New chroman and thiochroman derivatives
FR2670491B1 (fr) 1990-12-14 1993-02-05 Adir Nouvelles piperazines 1,4-disubstituees, leur procede de preparation et les compositions pharmaceutiques les renfermant.
MX9201991A (es) 1991-05-02 1992-11-01 Jonh Wyeth & Brother Limited Derivados de piperazina y procedimiento para su preparacion.
IT1251144B (it) 1991-07-30 1995-05-04 Boehringer Ingelheim Italia Derivati del benzimidazolone
GB9125900D0 (en) 1991-12-05 1992-02-05 Wyeth John & Brother Ltd Piperazine derivatives
EP0556889A1 (fr) 1992-02-18 1993-08-25 Duphar International Research B.V Méthode pour la préparation de aryl(homo)préparation
FR2692264B1 (fr) 1992-06-12 1994-08-05 Adir Nouvelles piperazines 1,4-disubstituees, leur procede de preparation et les compositions pharmaceutiques les contenant.
DK148392D0 (da) 1992-12-09 1992-12-09 Lundbeck & Co As H Heterocykliske forbindelser
DE69325698T2 (de) 1992-12-21 2000-01-27 Duphar Int Res Enzymatisches Verfahren zur stereoselektiven Herstellung einem Enantiomer aus einem hetero bicyclischen Alkohols
RU2118322C1 (ru) 1993-07-05 1998-08-27 Дюфар Интернэшнл Рисерч Б.В. 2,3-дигидро-1,4-бензодиокси-5-ил-пиперазиновые производные или их соли
WO1995003801A1 (fr) * 1993-07-28 1995-02-09 Nippon Shinyaku Co., Ltd. Antidepressif
WO1995011243A1 (fr) 1993-10-19 1995-04-27 Smithkline Beecham Plc Derives de benzanilide en tant qu'antagonistes du recepteur de 5ht-1d
EP0650964A1 (fr) 1993-11-02 1995-05-03 Duphar International Research B.V Dérivés de 1- 2H-1-benzopyran-2-one-8-yl -pipérazine
IL112764A0 (en) 1994-03-18 1995-05-26 Ferrer Int New chromene derivatives
MX9700080A (es) 1994-06-29 1997-04-30 Pfizer Derivados de aril y heteroaril alcoxinaftaleno.
FR2725623A1 (fr) * 1994-10-18 1996-04-19 Flamel Tech Sa Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os
EP0710481A1 (fr) 1994-11-02 1996-05-08 Duphar International Research B.V Emploi du flesinoxan comme stimulateur de la cognition
JPH10510253A (ja) 1994-12-07 1998-10-06 ビイク グルデン ロンベルク ヒェーミッシェ ファブリーク ゲゼルシャフト ミット ベシュレンクテル ハフツング ウラシル誘導体
US5741789A (en) * 1995-01-17 1998-04-21 Eli Lilly And Company Compounds having effects on serotonin-related systems
US6114334A (en) 1995-07-13 2000-09-05 Knoll Aktiengesellschaft Piperazine derivatives as therapeutic agents
GB9514901D0 (en) 1995-07-20 1995-09-20 American Home Prod Piperazine derivatives
SE9601110D0 (sv) * 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives
CZ294413B6 (cs) 1996-03-29 2004-12-15 Duphar International Research B. V. Piperazinová nebo piperidinová sloučenina, způsob její přípravy, farmaceutický prostředek tuto sloučeninu obsahující a použití této sloučeniny pro přípravu farmaceutického přípravku
US5846982A (en) * 1996-06-14 1998-12-08 Eli Lilly And Company Inhibition of serotonin reuptake
DK0932609T3 (da) 1996-10-15 2003-09-01 Wyeth Corp Azaheterocyclomethylderivater af 2,3,8,9-tetrahydro-7H-1,4-dioxino[2,3-e]indol-8-on
FR2760014B1 (fr) 1997-02-27 1999-04-09 Adir Nouveaux composes de 2-amino indane, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GB9706089D0 (en) * 1997-03-24 1997-05-14 Scherer Ltd R P Pharmaceutical composition
DE19730989A1 (de) * 1997-07-18 1999-01-21 Merck Patent Gmbh Piperazin-Derivate
WO1999005140A1 (fr) 1997-07-25 1999-02-04 H. Lundbeck A/S Derives indole et 2,3-dihydro-indole, leur preparation et utilisation
US5942244A (en) * 1997-07-31 1999-08-24 Farmo-Nat Ltd. Local oral herbal slow release tablets
ATE253058T1 (de) 1997-09-02 2003-11-15 Duphar Int Res Piperidin- und piperazin derivate als 5-ht1- rezeptor-agonisten
SE9703374D0 (sv) * 1997-09-18 1997-09-18 Astra Ab A new combination
SE9703375D0 (sv) * 1997-09-18 1997-09-18 Astra Ab A new combination
SE9703378D0 (sv) * 1997-09-18 1997-09-18 Astra Ab New compounds
SE9703376D0 (sv) * 1997-09-18 1997-09-18 Astra Ab A new combination
TW530054B (en) 1997-09-24 2003-05-01 Duphar Int Res New piperazine and piperidine compounds
FR2769312B1 (fr) 1997-10-03 1999-12-03 Adir Nouveaux composes de l'indanol, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
IL127497A (en) 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
US6310066B1 (en) 1998-04-29 2001-10-30 American Home Products Corp. Antipsychotic indolyl derivatives
US6387904B2 (en) 1998-05-18 2002-05-14 Pfizer Inc Method of treating glaucoma and ischemic retinopathy
EP0985414B1 (fr) 1998-05-26 2003-08-27 Pfizer Products Inc. Médicament pour le traitement du glaucôme et de la rétinopathie ischémique
GB9812523D0 (en) 1998-06-10 1998-08-05 Angeletti P Ist Richerche Bio Peptide inhibitors of hepatitis c virus ns3 protease
US6376494B1 (en) 1998-06-15 2002-04-23 American Home Products Corporation Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents
US6242448B1 (en) 1998-12-17 2001-06-05 American Home Products Corporation Trisubstituted-oxazole derivatives as serotonin ligands
US6313126B1 (en) 1999-01-07 2001-11-06 American Home Products Corp Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression
AR022303A1 (es) 1999-01-22 2002-09-04 Lundbeck & Co As H Derivados de piperidina, tetrahidropiridina y piperazina, su preparacion y utilizacion
US6306859B1 (en) 1999-03-02 2001-10-23 American Home Products Corporation N-substituted imide derivatives with serotonergic activity
ES2162731B1 (es) 1999-06-04 2003-02-16 Faes Fabrica Espanola De Produ Nuevas arilpiperacilnilalquil-3(2h)-piridacinonas.
DK1204654T3 (da) * 1999-07-29 2003-11-17 Lilly Co Eli Benzofurylpiperaziner og benzofurylhomopiperaziner: Serotonin agonister
ATE239722T1 (de) 1999-07-29 2003-05-15 Lilly Co Eli Benzofurylpiperazine als serotonin-agonisten
AR027133A1 (es) 1999-12-30 2003-03-12 Lundbeck & Co As H Derivados de heteroarilo, su preparacion y uso.
DZ3370A1 (fr) 2000-05-12 2001-11-15 Solvay Pharm Bv Composes de piperazine et piperidine
CA2405758A1 (fr) 2000-05-12 2001-11-15 Solvay Pharmaceuticals B.V. Utilisation de composes presentant une combinaison des activites de l'agoniste du recepteur adrenergique alpha, de la dopamine d2 et du 5-ht1a, pour le traitement de troubles du systeme nerveux central
US20020016334A1 (en) 2000-07-31 2002-02-07 Coe Jotham Wadsworth Pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD)
DE10041574A1 (de) 2000-08-24 2002-03-07 Merck Patent Gmbh Chromenonderivate
DE10043659A1 (de) 2000-09-05 2002-03-14 Merck Patent Gmbh Arylpiperazinderivate
US7034029B2 (en) * 2000-11-02 2006-04-25 Wyeth 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
EP2298738B1 (fr) * 2000-11-02 2012-09-19 Wyeth LLC 1-aryl- ou 1-alkylsulfonyl-heterocyclylbenzazoles en tant que ligands de 5-hydroxytryptamine-6
US6469007B2 (en) 2000-11-28 2002-10-22 Wyeth Serotonergic agents
ES2188344B1 (es) 2000-11-29 2004-09-16 Laboratorios Vita, S.A. Compuestos derivados de benzotiofeno, su procedimiento de obtencion y utilizacion de los mismos.
AR032711A1 (es) 2001-02-21 2003-11-19 Solvay Pharm Bv Derivados de fenilpiperazina, un metodo para la preparacion de los mismos y una composicion farmaceutica que los contiene
SK652004A3 (en) 2001-06-29 2004-09-08 Lundbeck & Co As H Heteroaryl derivatives, pharmaceutical composition with the content thereof and use of the same
ES2323451T7 (es) * 2001-07-20 2011-08-01 Psychogenics Inc. Tratamiento para el trastorno de hiperactividad con deficit de atencion.
HU227237B1 (en) 2001-09-27 2010-12-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Substituted alkylpyridazinone derivatives, process for their preparation, pharmaceutical compositions containing them
ITMI20012060A1 (it) 2001-10-05 2003-04-05 Recordati Chem Pharm Nuovi eterocilcli n-acilati
EP1336406A1 (fr) 2002-02-14 2003-08-20 Solvay Pharmaceuticals B.V. Agonistes partiels du récepteur D2 de la dopamine et inhibiteurs de la sérotonine et/ou de la noradrénaline
EP1483256A2 (fr) 2002-03-12 2004-12-08 Wyeth Methode de production de piperazines chiraux 1,4-disubstitues
IL163829A0 (en) 2002-03-12 2005-12-18 Wyeth Corp Preparation of N1-(2'-pyridyl)-1,2-propanediamine sulfamic acid and its use in the synthesis of biologically active piperazines
CA2477892C (fr) 2002-03-12 2010-11-23 Gregg Brian Feigelson Procede de synthese de piperazines n-aryle chirales
MXPA04011254A (es) 2002-05-13 2005-01-25 Hoffmann La Roche Derivados de benzoxazina como moduladores de 5-hidroxitriptamina 6 (5-ht6) y usos de los mismos.
US20040072839A1 (en) 2002-06-14 2004-04-15 Amedeo Leonardi 1-Phenylalkylpiperazines
US20040002500A1 (en) 2002-06-28 2004-01-01 Fabre Kramer Pharmaceutical, Inc. Methods for treating attention deficit disorder
US7067518B2 (en) 2002-09-05 2006-06-27 Wyeth Pyridinyl-methyl-ethyl cyclohexanecarboxamides as serotonergic agents
US7153849B2 (en) 2002-09-12 2006-12-26 Wyeth Antidepressant arylpiperazine derivatives of hetrocycle-fused benzodioxans
DK1562918T3 (da) 2002-11-08 2008-05-05 Hoffmann La Roche Substituerede benzoxazinoner og anvendelser deraf
US20040147581A1 (en) 2002-11-18 2004-07-29 Pharmacia Corporation Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
US20050004105A1 (en) 2003-01-29 2005-01-06 Emer Leahy Treatment for a attention-deficit hyperactivity disorder
DE602004010791T2 (de) 2003-03-03 2008-12-04 F. Hoffmann-La Roche Ag 2,5-substituiertetetrahydroisochinoline zur verwendung als 5-ht6 modulatoren
MXPA05012391A (es) 2003-05-16 2006-02-02 Pfizer Prod Inc Tratamiento de trastornos psicoticos y depresivos.
KR20060009938A (ko) 2003-05-16 2006-02-01 화이자 프로덕츠 인코포레이티드 양극성 장애 및 연관된 증상의 치료
MXPA05012325A (es) 2003-05-16 2006-01-30 Pfizer Prod Inc Procedimiento para potenciar la cognicion usando zipirasidona.
CA2525868A1 (fr) 2003-05-16 2004-11-25 Pfizer Products Inc. Traitements de l'angoisse avec la ziprasidone
US20050065158A1 (en) 2003-07-16 2005-03-24 Pfizer Inc. Treatment of sexual dysfunction
US7435738B2 (en) 2003-08-18 2008-10-14 Solvay Pharmaceuticals, Inc. Stable crystalline form of bifeprunox mesylate (7-[4-([1,1′-biphenyl]-3-ylmethyl)-1-piperazinyl]-2(3H)-benzoxazolone monomethanesulfonate)
US7160888B2 (en) 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
ES2291984T3 (es) 2003-12-09 2008-03-01 F. Hoffmann-La Roche Ag Derivados de benzoxazina y su empleo.

Also Published As

Publication number Publication date
US20060004023A1 (en) 2006-01-05
US20090104261A1 (en) 2009-04-23
WO2003007956A1 (fr) 2003-01-30
ES2323451T7 (es) 2011-08-01
JP5080716B2 (ja) 2012-11-21
US20110008425A1 (en) 2011-01-13
US7557109B2 (en) 2009-07-07
ES2323451T3 (es) 2009-07-16
AU2007254677B2 (en) 2009-11-12
ATE424825T1 (de) 2009-03-15
US7504395B2 (en) 2009-03-17
DK1408976T3 (da) 2009-06-29
EP1408976B1 (fr) 2009-03-11
AU2007254677A1 (en) 2008-01-24
EP1408976A4 (fr) 2007-05-16
JP2004538282A (ja) 2004-12-24
AU2002322539B2 (en) 2007-09-27
EP2036547A3 (fr) 2009-12-23
DE60231507D1 (de) 2010-07-01
EP2036547A2 (fr) 2009-03-18
EP1408976B3 (fr) 2010-08-25
CA2453837A1 (fr) 2003-01-30
CA2453837C (fr) 2011-10-04
US20120070494A1 (en) 2012-03-22
US20030050308A1 (en) 2003-03-13
DK1408976T5 (da) 2011-01-10
EP1408976A1 (fr) 2004-04-21

Similar Documents

Publication Publication Date Title
HK1065478A1 (en) Treatment for attention-deficit hyperactivity disorder
HK1087351A1 (en) Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit
ATE415968T1 (de) 3,11b-cis-dihydrotetrabanezin zur behandlung von schizophrenie und anderen psychosen
HK1097464A1 (en) Pharmaceutical compositions and methods for insulin treatment
HK1073608A1 (en) Treatment of alpha-galactosidase a deficiency
HRP20020593B1 (en) Brain, spinal and nerve injury treatment
EP1764092A3 (fr) Strategies therapeutiques pour la prevention et le traitement de la maladie d'alzheimer
EP1533395A4 (fr) Procede de fabrication d'un produit en acier inoxydable par traitement par absorption d'azote et produit en acier inoxydable obtenu selon ledit procede
HRP20050075A2 (en) Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
HK1080408A1 (en) Use of brimonidine in the treatment of dementia a nd parkinson
PL1603584T3 (pl) Aplidyna do leczenia szpiczaka mnogiego
ATE494307T1 (de) Neoplasma-spezifische antikörper und deren verwendungen
DE50300918D1 (de) Anlage zum sterilisieren, pasteurisieren und/oder desinfizieren pump- oder rieselfaehiger medien
ZA200101058B (en) Process for the treatment of gases.
AU2003265321A8 (en) Treatments and methods for the treatment, diagnosis and prophylaxis
EG23646A (en) An apparatus for driving one or more processing stations, and a chair for use in the apparatus
RU2002114913A (ru) Способ лечения вторичной гипоэстрогении
DE9314724U1 (de) Antriebs- und Beleuchtungseinrichtung für Krankenbetten, Behandlungsstühle u.dgl.
ATE300961T1 (de) Anlage zum sterilisieren, pasteurisieren und/oder desinfizieren pump- oder rieselfaehiger medien
RU2001112731A (ru) Способ лечения онкологических больных
ZA200307471B (en) Carbamate compounds for use in preventing or treating bipolar disorder.
TW200635580A (en) Methods of treatment and prevention
UA67138A (en) Method for treating chlamidia-associated reactive arthritis
ITPI20020050A1 (it) Bottale per le lavorazioni delle pelli.
UA51361A (uk) Спосіб лікування уражень суглобів

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20190719